
Oscar J Cordero

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7672469/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Immunology and immunotherapy in CRC. , 2022, , 435-453.		Ο
2	Population-based universal screening for CRC: Secondary prevention. , 2022, , 45-56.		0
3	Study of Plasma Anti-CD26 Autoantibody Levels in a Cohort of Treatment-NaÃ ⁻ ve Early Arthritis Patients. Archivum Immunologiae Et Therapiae Experimentalis, 2022, 70, 12.	2.3	2
4	The mechanism of sitagliptin inhibition of colorectal cancer cell lines' metastatic functionalities. IUBMB Life, 2021, 73, 761-773.	3.4	8
5	Distinctive CD26 Expression on CD4 T-Cell Subsets. Biomolecules, 2021, 11, 1446.	4.0	3
6	CD26-Related Serum Biomarkers: sCD26 Protein, DPP4 Activity, and Anti-CD26 Isotype Levels in a Colorectal Cancer-Screening Context. Disease Markers, 2020, 2020, 1-10.	1.3	12
7	Immunology and Immunotherapy of Colorectal Cancer. , 2020, , 261-289.		1
8	Naturally presented HLA class l–restricted epitopes from the neurotrophic factor S100â€Î² are targets of the autoimmune response in type 1 diabetes. FASEB Journal, 2019, 33, 6390-6401.	0.5	6
9	Surface expression marker profile in colon cancer cell lines and sphere-derived cells suggests complexity in CD26+cancer stem cells subsets. Biology Open, 2019, 8, .	1.2	25
10	Oral hygiene might prevent cancer. Heliyon, 2018, 4, e00879.	3.2	23
11	Activity and expression of dipeptidyl peptidase IV on peripheral blood mononuclear cells in patients with early steroid and disease modifying antirheumatic drugs naÃ`ve rheumatoid arthritis. Clinical Chemistry and Laboratory Medicine, 2017, 55, 73-81.	2.3	14
12	Apportioning Blame: Autoreactive CD4+ and CD8+ T Cells in Type 1 Diabetes. Archivum Immunologiae Et Therapiae Experimentalis, 2017, 65, 275-284.	2.3	12
13	Anti-CD26 autoantibodies are involved in rheumatoid arthritis and show potential clinical interest. Clinical Biochemistry, 2017, 50, 903-910.	1.9	13
14	CD26 Expression on T Helper Populations and sCD26 Serum Levels in Patients with Rheumatoid Arthritis. PLoS ONE, 2015, 10, e0131992.	2.5	19
15	Characterization of the autoimmune response against the nerve tissue S100β in patients with type 1 diabetes. Clinical and Experimental Immunology, 2015, 180, 207-217.	2.6	10
16	Serum dipeptidyl peptidase IV activity and sCD26 concentration in patients with choroidal nevus or uveal melanoma. Clinica Chimica Acta, 2015, 448, 193-194.	1.1	3
17	Stem and immune cells in colorectal primary tumour: Number and function of subsets may diagnose metastasis. World Journal of Immunology, 2015, 5, 68.	0.5	1
18	Evaluation of pleural effusion sCD26 and DPP-IV as diagnostic biomarkers in lung disease. Scientific Reports, 2014, 4, 3999.	3.3	18

OSCAR J CORDERO

#	Article	IF	CITATIONS
19	Postoperative Serum Levels of sCD26 for Surveillance in Colorectal Cancer Patients. PLoS ONE, 2014, 9, e107470.	2.5	17
20	Dipeptidyl peptidase IV: serum activity and expression on lymphocytes in different hematological malignancies. Leukemia and Lymphoma, 2013, 54, 2701-2706.	1.3	2
21	Serum activity of DPPIV and its expression on lymphocytes in patients with melanoma and in people with vitiligo. BMC Immunology, 2012, 13, 48.	2.2	18
22	Serum DPPIV activity and CD26 expression on lymphocytes in patients with benign or malignant breast tumors. Immunobiology, 2011, 216, 942-946.	1.9	25
23	Potential of soluble CD26 as a serum marker for colorectal cancer detection. World Journal of Clinical Oncology, 2011, 2, 245.	2.3	36
24	Data on the Interaction Between Prothymosin $\hat{I}\pm$ and TLR4 May Help to the Design of New Antiviral Compounds. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, e110-e111.	2.1	3
25	Serum CD26 is related to histopathological polyp traits and behaves as a marker for colorectal cancer and advanced adenomas. BMC Cancer, 2010, 10, 333.	2.6	27
26	Soluble CD26 Levels and Its Association to Epidemiologic Parameters in a Sample Population. Disease Markers, 2009, 27, 311-316.	1.3	12
27	On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunology, Immunotherapy, 2009, 58, 1723-1747.	4.2	185
28	Soluble CD26 levels and its association to epidemiologic parameters in a sample population. Disease Markers, 2009, 27, 311-6.	1.3	8
29	How the measurements of a few serum markers can be combined to enhance their clinical values in the management of cancer. Anticancer Research, 2008, 28, 2333-41.	1.1	13
30	Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma. British Journal of Cancer, 2007, 96, 1569-1578.	6.4	63
31	On the role of CD26 in CD4 memory T cells. Immunobiology, 2007, 212, 85-94.	1.9	6
32	Clinical Interest of the Combined Use of Serum CD26 and Alpha-L-Fucosidase in the Early Diagnosis of Colorectal Cancer. Disease Markers, 2004, 19, 267-272.	1.3	22
33	A Role for Interleukin-12 in the Regulation of T Cell Plasma Membrane Compartmentation. Journal of Biological Chemistry, 2003, 278, 24849-24857.	3.4	32
34	CD26 is Involved in the Regulation of T-Cell Plasma Membrane Compartmentation. , 2003, 524, 145-153.		0
35	Interleukinâ€dependent modulation of HLAâ€DR expression on CD4 and CD8 activated T cells. Immunology and Cell Biology, 2002, 80, 138-147.	2.3	40
36	Cell surface human α-L-fucosidase. FEBS Journal, 2001, 268, 3321-3331.	0.2	33

OSCAR J CORDERO

#	Article	IF	CITATIONS
37	Serum interleukin-12, interleukin-15, soluble CD26, and adenosine deaminase in patients with rheumatoid arthritis. Rheumatology International, 2001, 21, 69-74.	3.0	68
38	ldentification of Receptors for Prothymosin α on Human Lymphocytes. Biological Chemistry, 2001, 382, 1473-82.	2.5	11
39	Cytokines regulate membrane adenosine deaminase on human activated lymphocytes. Journal of Leukocyte Biology, 2001, 70, 920-30.	3.3	33
40	A ROLE FOR IL-12 ON THE REGULATION OF PLASMA MEMBRANE COMPARTMENTATION INVOLVED IN ANTIGEN-RECEPTOR FUNCTION. Biochemical Society Transactions, 2000, 28, A254-A254.	3.4	0
41	Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer. British Journal of Cancer, 2000, 83, 1139-1146.	6.4	73
42	MECHANISMS OF CD26/DIPEPTIDYL PEPTIDASE IV CYTOKINE-DEPENDENT REGULATION ON HUMAN ACTIVATED LYMPHOCYTES. Cytokine, 2000, 12, 1136-1141.	3.2	42
43	Fifteen years of prothymosin alpha: contradictory past and new horizons. Peptides, 2000, 21, 1433-1446.	2.4	90
44	Thymic peptides and preparations: an update. Archivum Immunologiae Et Therapiae Experimentalis, 1999, 47, 77-82.	2.3	2
45	Interleukin-12-dependent activation of human lymphocyte subsets. Immunology Letters, 1998, 61, 7-13.	2.5	19
46	Ecto-ADA in the development of theimmune system. Trends in Immunology, 1998, 19, 533.	7.5	10
47	Thymic Hormones and Peptides. , 1998, , 2300-2304.		1
48	Adenosine deaminase (ADA) isoenzymes ADA1 and ADA2 in biological fluids. European Respiratory Journal, 1997, 10, 2186-2187.	6.7	3
49	Interleukin-12 enhances CD26 expression and dipeptidyl peptidase IV function on human activated lymphocytes. Immunobiology, 1997, 197, 522-533.	1.9	62
50	Binding of 125I-prothymosin α to lymphoblasts through the non-thymosin α1 sequence. Life Sciences, 1996, 58, 1757-1770.	4.3	7
51	The presence and cytotoxicity of CD16+ CD2â^' subset from PBL and NK cells in long-term IL-2 cultures enhanced by Prothymosin-α. Immunopharmacology, 1995, 29, 215-223.	2.0	16
52	Prothymosin α Receptors on Lymphocytes. Journal of Interferon and Cytokine Research, 1995, 15, 731-737.	1.2	12
53	Prothymosin α receptors on peripheral blood mononuclear cells. FEBS Letters, 1994, 341, 23-27.	2.8	25
54	Interleukin-2 killer cells: in vitro evaluation of combination with prothymosin alpha. Lymphokine and Cytokine Research, 1994, 13, 175-82.	0.7	6

OSCAR J CORDERO

#	Article	IF	CITATIONS
55	On the anomalous behaviour on gel-filtration and SDS-electrophoresis of prothymosin-alpha. Biochemistry International, 1992, 28, 1117-24.	0.2	5
56	Prothymosin alpha enhances human natural killer cell cytotoxicity: role in mediating signals for NK activity. Lymphokine and Cytokine Research, 1992, 11, 277-85.	0.7	11
57	Prothymosin α enhances interleukin 2 receptor expression in normal human T-lymphocytes. International Journal of Immunopharmacology, 1991, 13, 1059-1065.	1.1	27
58	Phytohemagglutin-stimulated human T cell: prothymosin alpha as an accessory signal. Journal of Biological Regulators and Homeostatic Agents, 1990, 4, 7-12.	0.7	3
59	Rheumatoid arthritis patients show different levels of pro-inflammatory chemokine-cleaving enzyme CD26 on T cells, depending on the therapy. Frontiers in Immunology, 0, 4, .	4.8	0